Early Detection of OAB and Elimination of Negative Impact on Quality of Life
Early Detection of Overactive Bladder and Elimination of Negative Impact on Quality of Life
1 other identifier
interventional
1,000
1 country
20
Brief Summary
Overactive bladder (OAB) is one of the most common health problems in the adult population. The goal of this project is to improve the awareness of the problem and to correctly refer the targeted persons to a specialist or a doctor. This will be provided by an online screening tool, designed as web platform and mobile application, where the data will be stored in respect to GDPR. People with a positive result from the online screening tool will be offered an examination by a specialist (gynaecologist, urogynaecologist, urologist) involved in the project. The specialist will have access to the results from the online screening tool - he/she will log into the web platform with a view of the participants profile. He/she will perform the diagnosis, confirm or refute the diagnosis and complement it with any further diagnostic tests and set the standard treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Sep 2025
20 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2025
CompletedFirst Submitted
Initial submission to the registry
January 14, 2026
CompletedFirst Posted
Study publicly available on registry
January 27, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 31, 2026
January 27, 2026
January 1, 2026
10 months
January 14, 2026
January 22, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
Pilot testing with 1,000 participants
Pilot testing of the procedure on a sample of 1,000 people who will undergo an online self-diagnostic screening tool and be examined by a urogynecologist/urologist.
From enrollment to the end of examination in 3 months
Number of participants (completion of anonymous screening test)
Number of participants who complete anonymous screening test based on three questions reffering to urology health
from enrollment up to 1 week
Percentage of people with suspected OAB who agreed to participate in a follow-up examination with specialist
From enrollment up to 3 months
Percentage of people with a specialist confirmed diagnosis of OAB at the face-to-face visit
Through study completion, an average of 6 months
Percentage of people who attended follow-up examination after 3 months
Through study completion, an average of 9 months
Study Arms (1)
OAB Screening Arm
OTHERParticipants matching all the inclusion \& exclusion criteria will undergo a standardized screening process for the diagnosis of OAB. This process involves the use of an online screening self-testing tool, where the data from individual questionnaires specific to OAB diagnosis will be evaluated by a specialist.
Interventions
After completing the online screening tool (including validated questionnaires), selected participants are offered an appointment with a specialist who will perform a diagnosis, confirm or rule out OAB and set up adequate therapy according to recommended procedures.
Eligibility Criteria
You may qualify if:
- Signed Consent to Participate in the Project and Consent to the Processing of Personal Data (online and paper format)
- Men and women over 18 years of age with increased urinary frequency (more than 7 times in 24 hours)
- \- Nycturia and/or urge incontinence.
You may not qualify if:
- Unsigned Consent to Participate in the Project and Consent to the Processing of Personal Data.
- Current treatment of OAB, acute problems, suspicion of another disease causing OAB symptoms (haematuria, suspected bladder cancer, etc.)
- Inflammation of the lower urinary tract.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (20)
Brno University Hospital
Brno, Czechia
GYN-LINE, s.r.o.
Brno, Czechia
České Budějovice Hospital
České Budějovice, Czechia
Hospital Hořovice
Hořovice, Czechia
University Hospital Hradec Králové
Hradec Králové, Czechia
Hospital Jablonec nad Nisou
Jablonec nad Nisou, Czechia
AGYNO s.r.o.
Karlovy Vary, Czechia
Oblastní nemocnice Kolín a.s.
Kolín, Czechia
Olomouc University Hospital
Olomouc, Czechia
GYNOVA s.r.o.
Ostrava, Czechia
Hospital AGEL Ostrava - Vítkovice a.s.
Ostrava, Czechia
University Hospital Ostrava
Ostrava, Czechia
Gyncare Michael Švec s.r.o.
Pilsen, Czechia
Mulačova nemocnice
Pilsen, Czechia
General University Hospital
Prague, Czechia
GynUp! s.r.o.
Prague, Czechia
University Hospital Bulovka
Prague, Czechia
University Thomayer Hospital
Prague, Czechia
Uroklinikum s.r.o.
Prague, Czechia
Sokolov Hospital
Sokolov, Czechia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Jaromír Mašata, Professor
General University Hospital of Prague
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SCREENING
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 14, 2026
First Posted
January 27, 2026
Study Start
September 1, 2025
Primary Completion (Estimated)
June 30, 2026
Study Completion (Estimated)
August 31, 2026
Last Updated
January 27, 2026
Record last verified: 2026-01